Latest News

Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.

New research shows dermatologists continue to back daily sunscreen to prevent aging and skin cancer, debunking viral myths and spotlighting safer new filters coming to the US.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

Tattoo science goes skin deep, from ink placement and healing to adverse reactions, aftercare, and the dermatologic effects of pigment.

This review of the latest dermatological studies includes insights on brodalumab for plaque psoriasis, physiological characteristics of scalps with high sebum production, disease burden of anogenital PsO, and more.

Judson Brewer, MD, PhD, discussed how the trigger-behavior-result habit loop model can be applied to itch-scratch cycles in atopic dermatitis.

GBD 2021 shows urticaria burden in the Middle East and North Africa has stayed flat for 3 decades, but rates vary widely based on location, gender, age, and more.

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.

In the August letter from the editor in chief, Christopher Bunick, MD, PhD, explains bemotrizinol’s broad-spectrum UVA/UVB benefits and simple UV safety habits for sunscreen, pools, and wounds.

Our August issue tackles psoriasis, acne, aesthetics, sunscreen safety, and more.

Oral peptide pills are reshaping psoriasis care, from semaglutide breakthroughs to IL‑23 blocker icotrokinra—here's what dermatologists need to know now.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are pimple patches really that effective in clearing acne or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.